We are live on ! Find out more
IBRX icon

ImmunityBio

141 hedge funds and large institutions have $209M invested in ImmunityBio in 2021 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 47 increasing their positions, 35 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

79% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 19

34% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 35

12% more funds holding

Funds holding: 126141 (+15)

0.51% more ownership

Funds ownership: 8.16%8.67% (+0.51%)

33% less capital invested

Capital invested by funds: $311M → $209M (-$102M)

60% less call options, than puts

Call options by funds: $2.96M | Put options by funds: $7.39M

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
141
Holders Change
+15
Holders Change %
+11.9%
% of All Funds
2.17%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
34
Increased
47
Reduced
35
Closed
19
Calls
$2.96M
Puts
$7.39M
Net Calls
-$4.43M
Net Calls Change
+$3.53M

IBRX Hedge Fund Activity: Q4 2021 in Review

141 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2021, worth a combined $209M — down 33% from $311M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new IBRX positions and 19 closed out — a net gain of 15 holders — while 47 added to existing stakes and 35 trimmed.

The largest buyer was State Street, adding an estimated $6.74M. The largest seller was Northern Trust, cutting an estimated $4.31M.

  • 141 institutional investors held ImmunityBio (IBRX) as of Q4 2021, up from 126 in Q3 2021.
  • Funds reported $209M of ImmunityBio stock for Q4 2021, down 33% quarter-over-quarter.
  • 34 funds opened new ImmunityBio positions in Q4 2021 and 19 closed out, a net change of +15 holders.
  • The largest ImmunityBio buyer in Q4 2021 was State Street, an estimated $6.74M added.
  • The largest ImmunityBio seller in Q4 2021 was Northern Trust, an estimated $4.31M sold.

Based on aggregated 13F filings for Q4 2021.